J Bone Metab.  2015 Nov;22(4):183-189. 10.11005/jbm.2015.22.4.183.

Effect of Teriparatide on Healing of Atypical Femoral Fractures: A Systemic Review

• Im GI
• Lee SH

• KMID: 2170126
• DOI: http://doi.org/10.11005/jbm.2015.22.4.183

Abstract

BACKGROUND
Bisphosphonates (BPs) are the most commonly used anti-osteoporotic drugs, which have been proven to reduce the risk of osteoporotic fractures. However, use of BPs, particularly for long periods of time, is associated with an increased risk of atypical femoral fracture (AFF). Healing of BP-associated AFF is usually delayed because of suppressed bone turnover. Teriparatide (TPTD), a recombinant form of parathyroid hormone (PTH), enhances bone healing in patients with delayed healing or non-union.
METHODS
In this study, we summarized and performed a systemic review of the published literature on treatment of AFF using TPTD.
RESULTS
Although there is a lack of level 1 studies on the evidence of TPTD in promoting bone union in AFFs, this systemic review of the available literature revealed that TPTD works positively in AFFs, and we put together the evidence that TPTD is a viable treatment option for enhancing fracture healing in AFFs.
CONCLUSIONS
While anecdotal evidence of beneficial effects of TPTD on fracture healing offer limited guidance for clinical decision making, a better understanding of the role of TPTD in fracture healing may be elucidated with future prospective trials.

Keyword

Biphosphonates; Femoral fractures; Parathyroid hormone; Teriparatide

MeSH Terms

Decision Making
Diphosphonates
Femoral Fractures*
Fracture Healing
Humans
Osteoporotic Fractures
Parathyroid Hormone
Prospective Studies
Teriparatide*
Diphosphonates
Parathyroid Hormone
Teriparatide

Figure

• 

  Fig. 1 Flow chart of article selection process.

Reference

1. Iwamoto J, Makita K, Sato Y, et al. Alendronate is more effective than elcatonin in improving pain and quality of life in postmenopausal women with osteoporosis. Osteoporos Int. 2011; 22:2735–2742.

2. Lyles KW, Colón-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007; 357:1799–1809.

3. McClung M, Harris ST, Miller PD, et al. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med. 2013; 126:13–20.

4. Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014; 29:1–23.

5. Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010; 25:2267–2294.

6. Koh JS, Goh SK, Png MA, et al. Femoral cortical stress lesions in long-term bisphosphonate therapy: a herald of impending fracture? J Orthop Trauma. 2010; 24:75–81.

7. Park-Wyllie LY, Mamdani MM, Juurlink DN, et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA. 2011; 305:783–789.

8. Seeman E. Bone morphology in response to alendronate as seen by high-resolution computed tomography: through a glass darkly. J Bone Miner Res. 2010; 25:2553–2557.

9. Currey JD. Bone architecture and fracture. Curr Osteoporos Rep. 2005; 3:52–56.

10. Karim L, Vashishth D. Role of trabecular microarchitecture in the formation, accumulation, and morphology of microdamage in human cancellous bone. J Orthop Res. 2011; 29:1739–1744.

11. Currey J. Structural heterogeneity in bone: good or bad? J Musculoskelet Neuronal Interact. 2005; 5:317.

12. Egol KA, Park JH, Rosenberg ZS, et al. Healing delayed but generally reliable after bisphosphonate-associated complete femur fractures treated with IM nails. Clin Orthop Relat Res. 2014; 472:2728–2734.

13. Thompson RN, Phillips JR, McCauley SH, et al. Atypical femoral fractures and bisphosphonate treatment: experience in two large United Kingdom teaching hospitals. J Bone Joint Surg Br. 2012; 94:385–390.

14. Gallacher SJ, Dixon T. Impact of treatments for postmenopausal osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate, and denosumab) on bone quality: a systematic review. Calcif Tissue Int. 2010; 87:469–484.

15. Miyakoshi N. Effects of parathyroid hormone on cancellous bone mass and structure in osteoporosis. Curr Pharm Des. 2004; 10:2615–2627.

16. Pietrogrande L, Raimondo E. Teriparatide in the treatment of non-unions: scientific and clinical evidences. Injury. 2013; 44:Suppl 1. S54–S57.

17. Alkhiary YM, Gerstenfeld LC, Krall E, et al. Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34). J Bone Joint Surg Am. 2005; 87:731–741.

18. Bostrom MP, Gamradt SC, Asnis P, et al. Parathyroid hormone-related protein analog RS-66271 is an effective therapy for impaired bone healing in rabbits on corticosteroid therapy. Bone. 2000; 26:437–442.

19. Komrakova M, Stuermer EK, Werner C, et al. Effect of human parathyroid hormone hPTH (1-34) applied at different regimes on fracture healing and muscle in ovariectomized and healthy rats. Bone. 2010; 47:480–492.

20. Mognetti B, Marino S, Barberis A, et al. Experimental stimulation of bone healing with teriparatide: histomorphometric and microhardness analysis in a mouse model of closed fracture. Calcif Tissue Int. 2011; 89:163–171.

21. Rowshan HH, Parham MA, Baur DA, et al. Effect of intermittent systemic administration of recombinant parathyroid hormone (1-34) on mandibular fracture healing in rats. J Oral Maxillofac Surg. 2010; 68:260–267.

22. Aspenberg P, Genant HK, Johansson T, et al. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res. 2010; 25:404–414.

23. Chiang CY, Zebaze RM, Ghasem-Zadeh A, et al. Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy. Bone. 2013; 52:360–365.

24. Lee YK, Ha YC, Kang BJ, et al. Predicting need for fixation of atypical femoral fracture. J Clin Endocrinol Metab. 2013; 98:2742–2745.

25. Gomberg SJ, Wustrack RL, Napoli N, et al. Teriparatide, vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy. J Clin Endocrinol Metab. 2011; 96:1627–1632.

26. Carvalho NN, Voss LA, Almeida MO, et al. Atypical femoral fractures during prolonged use of bisphosphonates: short-term responses to strontium ranelate and teriparatide. J Clin Endocrinol Metab. 2011; 96:2675–2680.

27. Fukuda F, Kurinomaru N, Hijioka A. Weekly Teriparatide for Delayed Unions of Atypical Subtrochanteric Femur Fractures. Biol Ther. 2014; DOI: 10.1007/s13554-014-0013-5.

28. Huang HT, Kang L, Huang PJ, et al. Successful teriparatide treatment of atypical fracture after long-term use of alendronate without surgical procedure in a postmenopausal woman: a case report. Menopause. 2012; 19:1360–1363.

29. Lampropoulou-Adamidou K, Tournis S, Balanika A, et al. Sequential treatment with teriparatide and strontium ranelate in a postmenopausal woman with atypical femoral fractures after long-term bisphosphonate administration. Hormones (Athens). 2013; 12:591–597.

30. Tarazona-Santabalbina FJ, Aguilella-Fernández L. Bisphosphonate long-term treatment related bilateral subtrochanteric femoral fracture. Can teriparatide be useful? Aging Clin Exp Res. 2013; 25:605–609.

31. Tsuchie H, Miyakoshi N, Nishi T, et al. Combined effect of a locking plate and teriparatide for incomplete atypical femoral fracture: two case reports of curved femurs. Case Rep Orthop. 2015; 2015:213614.

32. Miyakoshi N, Aizawa T, Sasaki S, et al. Healing of bisphosphonate-associated atypical femoral fractures in patients with osteoporosis: a comparison between treatment with and without teriparatide. J Bone Miner Metab. 2015; 33:553–559.

33. Saleh A, Hegde VV, Potty AG, et al. Management strategy for symptomatic bisphosphonate-associated incomplete atypical femoral fractures. HSS J. 2012; 8:103–110.

34. Miller PD, McCarthy EF. Bisphosphonate-associated atypical sub-trochanteric femur fractures: paired bone biopsy quantitative histomorphometry before and after teriparatide administration. Semin Arthritis Rheum. 2015; 44:477–482.

35. Murphy CM, Schindeler A, Cantrill LC, et al. PTH(1-34) treatment increases bisphosphonate turnover in fracture repair in rats. J Bone Miner Res. 2015; 30:1022–1029.